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Abstract
Background: Anti-Müllerian hormone (AMH) is currently used as an ovarian reserve marker for individualized
fertility counseling, but very little is known of individual AMH decline in women. This study assessed whether the
decline trajectory of AMH is uniform for all women, and whether baseline age-specific AMH levels remain
consistently high or low during this trajectory.
Methods: A total of 3326 female participants from the population-based Doetinchem Cohort Study were followed
with five visits over a 20-year period. Baseline age was 40 ± 10 years with a range of 20–59 years.
AMH was measured in 12,929 stored plasma samples using the picoAMH assay (AnshLabs). Decline trajectories of
AMH were studied with both chronological age and reproductive age, i.e., time to menopause. Multivariable linear
mixed effects models characterized the individual AMH decline trajectories.
Results: The overall rate of AMH decline accelerated after 40 years of age. Mixed models with varying age-specific
AMH levels and decline rates provided the significantly best fit to the data, indicating that the fall in AMH levels
over time does not follow a fixed pattern for individual women. AMH levels remained consistent along individual
trajectories of age, with an intraclass correlation coefficient (ICC) of 0.87. The ICC of 0.32 for AMH trajectories with
time to menopause expressed the large variation in AMH levels at a given time before the menopause. The
differences between low and high age-specific AMH levels remained distinguishable, but became increasingly
smaller with increasing chronological and reproductive age.
Conclusions: This is the first study to characterize individual AMH decline over a long time period and broad age
range. The varying AMH decline rates do not support the premise of a uniform AMH decline trajectory. Although
age-specific AMH levels remain consistently high or low with increasing age, the converging trajectories and
variance of AMH levels at a given time before menopause shed doubt on the added value of AMH to represent
individualized reproductive age.
Background
Women are born with an endowment of oocytes, which
decreases as they age. The decline in oocyte quantity
eventually leads to menopause, marking the end of the
reproductive lifespan [1]. The ability to achieve spontan-
eous pregnancies ceases several years before the onset of
menopause [2], and is thought to be related to the quality
of remaining oocytes. With an ever-expanding societal
tendency to delay childbearing to a later age, more women
may thus unknowingly surpass their window of fertile
years due to a decline in oocyte quality and quantity.
Over the past decades, many research efforts have aimed
at quantifying the remaining pool of oocytes, otherwise
known as the ovarian reserve. Anti-Müllerian hormone
(AMH), produced by follicular granulosa cells, has recently
emerged as a promising biomarker representing the
number of remaining follicles in the ovaries [1]. Herein,
AMH levels are suggested to provide an estimation of
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‘reproductive age’, irrespective of chronological age [3–11].
In other words, a woman with a low AMH level would
have a lower ovarian reserve, and thus a shorter time to
menopause than a woman with a higher AMH level of the
same (chronological) age. This concept has found its way
into clinical practice, as women are currently receiving
personalized family planning or fertility treatment counsel-
ing based on their AMH levels. Although this may seem
like an advancement in reproductive healthcare, evidence
to support this practice is lacking. Current knowledge of
AMH is scarce, and limited by the use of a single
measurement [12–18], small study populations [5, 8, 19],
selected study groups rather than a population-based
approach [5, 8, 12–18], theoretical rather than empiric
models [20, 21], and restricted age ranges [12, 15]. The
individualized use of AMH as an indicator of the repro-
ductive lifespan is therefore still hampered by two main
questions.
First, little is known about whether the rate by which
AMH declines is the same for all women. In other words,
are individual AMH decline trajectories parallel to one
another, or not? Secondly, the value of a single AMH
measurement remains elusive, can a woman with a high
age-specific AMH level at 20 years be expected to also
have a high age-specific value at age 35, and what does
this mean for her trajectory with reproductive age, i.e.,
time to menopause? We aimed to answer these two ques-
tions by characterizing the longitudinal decline trajectories
of AMH in relation to both chronological age and time to
menopause in a large population-based study.
Methods
Study population
Our study population consisted of the female participants
of the Doetinchem Cohort Study. The Doetinchem Cohort
is a population-based cohort, whose participants were
randomly recruited from the Doetinchem area of the
Netherlands in 1987 [22]. The objective of the Doetinchem
Cohort Study is to observe the impact of lifestyle and
biological factors on chronic disease occurrence and quality
of life [22]. At the time of recruitment, participants were
aged between 20 and 59 years. After the baseline visit
(round 1), participants were invited for follow-up every
5 years. At the time of the study, rounds 1 through 5 had
been completed, leading to an approximate follow-up time
of 20 years.
At each visit, lifestyle, general health, and reproductive
history were assessed through extensive questionnaires,
and biometric and laboratory measurements were per-
formed. In addition to the laboratory measurements that
were performed directly after each consecutive blood
withdrawal, aliquots with additional plasma samples of
each participant were immediately stored for future use.
All participants provided written informed consent and
ethical approval was granted by the Medical Ethics
Committee of the Netherlands Organization of Applied
Scientific Research. The use of stored sample specimens
was ethically approved by the Ethical Committee for
Biobank Studies of the University Medical Center Utrecht.
Only female participants from the Doetinchem Cohort
with at least one available stored plasma sample, regardless
of their age or menopausal status, were eligible for the
current study. Of the total number of 4128 participating
women, 3326 had an available plasma sample for at least
one of the follow-up rounds. Rounds 1–5 comprised
plasma samples of 3133, 2914, 2507, 2324, and 2051
women, respectively.
AMH measurements
The plasma samples from round 1 were stored in EDTA
aliquots at –30 °C. The samples derived from rounds 2–5
were stored in EDTA aliquots at –80 °C. Prior to the
current study, the samples were thawed once for additional
measurements and immediately refrozen. For the current
study, stored plasma samples of rounds 1–5 were utilized.
In March 2015, all the available samples of each participant
had been retrieved from storage and were shipped on dry
ice to AnshLabs (Webster, Texas, USA), where they were
temporarily stored at –20 °C until the analyses were
performed. AMH levels were measured with the picoAMH
assay (AnshLabs), because of its low limit of detection and
the small aliquot size necessary, which is crucial for cohort
studies with a limited pool of biological samples. The
plasma samples of each individual were measured in a
single assay run, by a single laboratory operator. In total,
two laboratory operators performed all measurements. At
a mean level of 91.2 pg/mL, the coefficient of variation was
4.0 %. At 290.3 pg/mL, the coefficient of variation was
4.8 %. The limit of quantification was 3.0 pg/mL and the
limit of detection 1.8 pg/mL. There were no indications of
plate drift, with all coefficients of variation within plate
columns and rows under 5 %.
Time to menopause
Age at the time of the final menstrual period (FMP) was
assessed by taking into account questionnaire information
of cycle regularity, number of menstrual periods in the
prior 12 months, oral contraceptive (OC) use, pregnancy,
reproductive surgery, and self-reported age at menopause.
Due to slightly differing questionnaires throughout the
follow-up rounds, the assessment of the timing of the
FMP differed per round. The earliest estimation of the
timing of the FMP was considered to be the most accur-
ate, being the most proximate to the event. Time to
menopause was calculated by subtracting a participant’s
age at the FMP from her age at follow-up. Women who
ever underwent a bilateral oophorectomy were excluded
from this calculation in order to obtain the time to natural
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menopause at each follow-up round. Women who
underwent a hysterectomy before the onset of natural
menopause were considered to have an unknown age at
menopause.
Missing data
For information on smoking, OC use, menstrual cycle
regularity in rounds 1, 4, and 5, age at menarche, and body
mass index (BMI), the percentage of missing information
was below 2 %. In rounds 2 and 3, missing information for
cycle status was 6.8 % and 14.6 %, due to missing informa-
tion of the date of the last menstrual period. Missing
information for hormone replacement therapy use
increased with each round, and varied between 7.1 % and
59.8 %. Multiple imputation through predictive mean
matching with 10 iterations was performed for these
variables, including participant ID, age, and AMH levels
solely as predictor variables, and all remaining variables
both as predictors and outcomes. Multiple imputation
was performed with R (http://www.R-project.org), using
the ‘mice’ library (http://www.jstatsoft.org/v45/i03/).
Assessment of individual decline rate: parallel or
non-parallel trajectories
To assess whether the decline rate of AMH differed for
individuals, AMH trajectories in relation to age and time
to menopause were fitted with a mixed model approach
using the ‘lme4’ package in R. Mixed models enable the
evaluation of multilevel longitudinal data, and are thus
able to take into account multiple measurements over
time for each participant, with varying AMH levels (i.e.,
random intercept) and decline rates (i.e., random slope)
for each individual. As AMH had a skewed distribution,
AMH levels were logarithmically transformed. Levels
below the detection limit of 0.0018 ng/mL were set at this
level for the purpose of logarithmic transformation.
LogAMH was used as the outcome of the mixed models,
with chronological age or time to menopause as the time
variable and participant ID as the group indicator variable.
We modeled age and time to menopause with non-linear
natural splines and checked the significance of non-
linearity (a P value of < 0.05 indicated significant non-
linearity). Models were adjusted for current OC use and
OC use 5 years prior, hormone replacement therapy use,
and current smoking and smoking 5 years prior, as these
determinants were associated with the longitudinal AMH
levels (data not shown). To decide whether women had
differing age-specific AMH levels, differing decline rates,
or both, the multivariable-adjusted models with a random
intercept, slope or both, were compared to models with
only fixed terms for these two parameters. The Akaike
Information Criterion (AIC) of the models was used for
this purpose. A lower AIC by at least 2 points represented
a significantly better fit of the data.
Assessment of the consistency of age-specific AMH levels:
does high remain high and vice versa?
To get an indication of whether individual AMH levels
that were relatively low or high based on age remained
comparatively low or high as time progressed, women
were divided into age-standardized AMH quartiles in
round 1. The CG-LMS method, previously described in
detail by Dólleman et al. [23], was used for age
standardization. The AMH decline trajectory of women
in these four quartile groups was then plotted against
chronological age and time to menopause.
In order to measure whether the AMH levels of the
individual participants remained on a single trajectory,
and did not vary between the 95th and 5th percentile over
time for example, the variance of AMH measurements
within and between individuals was assessed for the final
mixed models. By dividing the between-individual
variance by the total variance (between-individual +
within-individual variance), the intraclass correlation coef-
ficient (ICC) was calculated. The ICC gives an indication
of the correlation of AMH measurements on each individ-
ual’s trajectory, which is directly relative to the amount of
variation between individuals. For AMH decline with age,
we hypothesized that women would follow a consistent
high or low trajectory, i.e., that the variance of their AMH
levels around a trajectory would be low. We therefore
postulated that most of the variance would arise from
differences in AMH levels between individuals, in which
case the ICC would approach 1. For AMH decline with
time to menopause, we hypothesized that there would be
little variance of AMH levels between individuals; for
example, we expected that the AMH level at 10 years
before menopause would be roughly similar across the
whole group. In this case, the ICC would approach 0.
Participant involvement
Participants of the Doetinchem Cohort were not directly
involved in the formulation of the study question or
realization of the study design. As this was a population-
based study design, patients were not involved.
Results
Population characteristics
On average, women in the study population completed
3.1 visits, and 79 % of the participants completed two or
more visits. The longest follow-up time was 21 years. In
Table 1, the participant characteristics per follow-up
round are presented. The number of women and their
characteristics at each visit are listed per 5-year age
groups in Additional file 1: Tables S1–S6. The youngest
age at baseline was 20 years and the highest age at the
end of follow-up was 81 years. At baseline, 18 % of the
women were aged between 20 and 30 years, and 32 %
were aged between 30 and 40 years. At each visit, the
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percentage of OC users and smokers decreased with
increasing age (Table 1, Additional file 1: Tables S1–S3).
The percentage of smokers within the same age categor-
ies (thus comprising different women at each visit)
decreased over time. BMI levels increased both with age
and over time within the same age categories, meaning
that, on average, a 40-year-old woman had a lower BMI
in 1987 than in 2007 (Table 1, Additional file 1: Table
S4). Within the entire study population, the median
(interquartile range (IQR)) ages at menarche and FMP
were 13 (12–15) and 50 (48–53), respectively.
By the end of follow-up (visit 5), there were 1882
women with a known age at menopause. In total, 440
women (13.2 %) underwent a hysterectomy, 139 women
(4.2 %) had a unilateral oophorectomy, and 77 women
(2.3 %) had a bilateral oophorectomy. The women with no
available blood samples had similar baseline characteris-
tics to the study population with regards to age, age at
menarche, age at FMP, and OC use. They smoked more
frequently at baseline (41.9 % vs. 33.6 %, P < 0.001) and
had a higher average BMI (25.9 vs. 24.6 kg/m2, P < 0.001).
General AMH decline
AMH levels decreased with age and remained relatively
stable over time within the visit-specific age categories
(Additional file 1: Table S6). The percentage of AMH
levels below the lower limit of detection reached a max-
imum of 88.3 % between the ages of 61 and 65 years
(Additional file 1: Table S7). In Table 2, the observed
AMH levels and number of measurements below the
level of detection are listed for fixed chronological age
and time to menopause points. Each individual AMH
trajectory over age and time to menopause is depicted in
Fig. 1. The decline patterns were not linear, but appeared
to follow a sigmoid-shaped trajectory, indicating that the
overall rate of AMH change differed depending on age
and time to menopause. Generally, the decline rate
appeared to be relatively low until 40 years, after which
there was an apparent acceleration until a plateau at the
lower limit of detection around the age of 55 was reached.
There also appeared to be an acceleration of the overall
decline rate with time to menopause at 10 years before
the FMP, although this acceleration seemed more gradual
than with age.
Assessment of individual decline rate: parallel or non-parallel
trajectories
Chronological age
For AMH decline with age, the best fitting mixed models
incorporated a random slope and random intercept and
were significantly non-linear. The random slopes indicate
that individual women had differing decline rates, and the
non-linearity indicates that the overall rate of decline
varied with age. Based on the multivariable-adjusted AMH
levels, the rate of change in various age intervals was
assessed per participant (Table 3). The average rate of
AMH decline was greatest between 45 and 50 years of age.
Because the AMH decline rates with age differed
between participants, we plotted the adjusted AMH
levels at age 20 against the decline rate at different age
intervals in order to estimate whether there was a
relationship between AMH levels and rate of decline. As
seen in Fig. 2a, women who had a higher adjusted AMH
level at age 20 had a slower decline rate between the
ages of 20 and 25. This was also true between the ages
of 25 and 40 years, whereas between the ages of 40 and
45 all women had approximately equal decline rates,
regardless of their adjusted AMH levels at age 20. In
contrast, after age 45, women with higher AMH levels at
age 20 had a faster decline rate.
Table 1 Population characteristics per follow-up round
Round 1
n = 3133
Round 2
n = 2914
Round 3
n = 2507
Round 4
n = 2324
Round 5
n = 2051
Age, years 40 ± 10 46 ± 10 50 ± 10 55 ± 10 59 ± 10
OC use 32 25 21 12 8
HRT use 0 4 4 2 2
Smoker 34 31 26 22 18
BMI, kg/m2 25 ± 4 26 ± 4 26 ± 4 27 ± 5 27 ± 5
Regular cyclea 60 54 45 20 10
Premenopausal 86 66 54 48 36
Pregnant 2 1 1 0 0
Numbers are given in % or mean ± SD
aOC users excluded
OC oral contraceptive, HRT hormone replacement therapy, BMI body
mass index
Table 2 Observed anti-Müllerian hormone (AMH) levels and
proportion of undetectable levels at specified ages and time
points before and after menopause
AMH (ng/mL) <0.0018 ng/mL
Age (years)
20 3.86 (2.66–5.28) 0 (0)
30 2.84 (1.88–4.86) 0 (1)
40 0.93 (0.40–2.00) 1 (3)
50 0.01 (0.00–0.08) 28 (61)
60 0.00 (0.00–0.00) 82 (111)
Time to menopause (years)
20 3.61 (2.25–6.28) 0 (0)
15 2.06 (0.94–3.28) 0 (0)
10 0.82 (0.50–1.51) 1 (1)
5 0.18 (0.08–0.34) 4 (7)
0 0.00 (0.00–0.01) 37 (76)
+5a 0.00 (0.00–0.00) 73 (139)
Numbers indicate median (IQR) and % (n), respectively
a5 years after the final menstrual period
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Time to menopause
For time to menopause, the best fitting mixed models
incorporated a random slope and random intercept and
were significantly non-linear. Thus, individual women
had differing AMH levels and decline rates, and the rate
of decline varied with time to menopause. In Table 3, the
multivariable-adjusted rate of change per time to meno-
pause interval is displayed, indicating that the average
decline rate gradually decreased closer to the menopause.
A higher AMH level at 20 years before the FMP was asso-
ciated with a slower decline rate of AMH between 20 and
15 years before the FMP (Fig. 2b). In the last 5 years
before the FMP, this relationship reversed, such that a
high AMH level at 20 years before the FMP was associ-
ated with a faster AMH decline rate.
Assessment of the consistency of age-specific AMH levels:
does high remain high and vice versa?
Chronological age
According to the distribution of AMH with age at
baseline, women were divided into age-specific AMH
quartiles. The overall decline trajectory of each quartile
group with chronological age is depicted in Fig. 3a. The
difference between low and high age-specific AMH levels
was maintained with increasing age, but the absolute
difference became smaller. The ICC of the mixed model
for AMH decline with age was 0.87, indicating that 13 %
of the total variance could be accounted for by variability
within individual AMH decline trajectories with age.
Including only regularly cycling women at baseline
(n = 2070), the ICC was 0.93, leaving 7 % of the total
variance to be explained by variability within individ-
ual trajectories.
Time to menopause
The overall decline trajectory of each age-specific AMH
quartile group with time to menopause is depicted in
Fig. 3b. The difference between low and high age-specific
AMH levels was distinguishable from 20 years before
menopause to the FMP, but the absolute differences
became smaller as women neared their FMP. The ICC for
Fig. 1 Decline of anti-Müllerian hormone (AMH) with chronological age (a) and time to menopause (b). Each line represents an individual
trajectory based on observed AMH levels
Table 3 Estimated rate of anti-Müllerian hormone (AMH) change
per time interval for age and per time interval to menopause,
based on multivariable-adjusted mixed models
5-year rate of change 1-year rate of change
Age period (years)
20–25 0.05 ± 0.86 (–3.1 to 3.3) 0.01 ± 0.17 (–0.63 to 0.66)
25–30 –0.12 ± 0.78 (–2.9 to 2.8) –0.02 ± 0.16 (–0.59 to 0.56)
30–35 –0.46 ± 0.60 (–2.6 to 1.9) –0.09 ± 0.12 (–0.51 to 0.37)
35–40 –0.97 ± 0.35 (–2.0 to 0.42) –0.19 ± 0.07 (–0.40 to 0.08)
40–45 –1.65 ± 0.13 (–2.3 to –0.3) –0.33 ± 0.03 (–0.46 to –0.05)
45–50 –2.2 ± 0.37 (–3.5 to 0.3) –0.43 ± 0.08 (–0.71 to 0.05)
50–55 –1.9 ± 0.46 (–3.6 to 0.3) –0.38 ± 0.09 (–0.71 to 0.06)
55–60 –0.95 ± 0.37 (–2.4 to 0.4) –0.19 ± 0.07 (–0.47 to 0.07)
Time to menopause period (years)
20–15 –2.18 ± 0.65 (–3.75 to –0.30) –0.44 ± 0.13 (–0.75 to –0.06)
15–10 –2.11 ± 0.48 (–3.25 to –0.70) –0.42 ± 0.10 (–0.65 to –0.14)
10–5 –1.98 ± 0.17 (–2.58 to –1.39) –0.39 ± 0.03 (–0.52 to –0.28)
5–0 –1.78 ± 0.32 (–2.87 to –0.80) –0.36 ± 0.06 (–0.57 to –0.16)
Numbers indicate mean ± standard deviation (range) difference in individual
logAMH levels between specified age and time to menopause intervals
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time to menopause was 0.32 for the whole group (n = 1882)
and 0.31 for only the baseline regular cyclers (n = 1046),
meaning that approximately one-third of the total variance
arose from between-individual differences in AMH levels.
Thus, differences between high and low age-specific AMH
levels were also distinguishable before menopause, but
there was more overlap of AMH trajectories with time to
menopause than with chronological aging.
Discussion
With this longitudinal study, we are able to shed light
on the individual decline of AMH. We found that AMH
trajectories with age and time to menopause were not
identical, as the rate of decline differed between individ-
uals. The rate of AMH decline was dependent on initial
AMH levels, and this relationship differed with age and
time to menopause. The evident differences between
women with relatively high and low age-specific AMH
levels at baseline became increasingly smaller as time
progressed. The AMH levels of an individual woman
correlated well with one another and thus did not deviate
far from her trajectory. Contrary to our expectations,
there was considerable variation of AMH levels between
individuals with time to menopause. Taken together, these
Fig. 2 Association of multivariable-adjusted baseline anti-Müllerian hormone (AMH) level with rate of change in different time intervals. Colored
lines indicate varying time intervals. a A higher AMH level at age 20 was associated with a slower decline rate between the ages of 20 and 25
(blue line), and a higher decline rate between the ages of 55 and 60 (orange line). b A higher AMH level at 20 years before the final menstrual
period (FMP) was associated with a slower decline rate between 20 and 15 years before the FMP (blue line) and a higher decline rate in the 5 years
before the FMP (pink line)
Fig. 3 Anti-Müllerian hormone (AMH) decline with age and time to menopause. White lines represent individual trajectories based on observed
AMH levels. Colored lines represent the group trajectories of women based on baseline age-specific AMH quartiles and gray areas indicate the
standard error of a group trajectory. a The trajectories of women in the baseline age-specific AMH quartiles are distinguishable until they overlap
between ages 55 and 60. The difference between women in low and high age-specific quartiles is largest at age 20. b The trajectories of women
in the baseline age-specific AMH quartiles are distinguishable until they overlap around 5 years before the final menstrual period. The difference
between women in low and high age-specific quartiles is largest at 20 years before the final menstrual period
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results indicate that women do not all follow the same
decline trajectory of AMH, and that the largest differences
in AMH levels between women can be found in early
adult and reproductive life, after which they become
increasingly smaller.
In a study of 81 fertile women, the variation of two
AMH levels measured over an interval of 4 years was
compared per study participant [24]. AMH levels were
strongly associated with chronological age, and the
change of individual AMH levels was comparable with
the overall group decline (with a within-individual
residual correlation of 0.66) [24]. Our results indicate
that there is indeed a high within-individual correlation
of AMH levels over a long trajectory with age, which
appeals to the reliability of multiple AMH measures to
estimate the trajectory of an individual.
Building an overall model for AMH decline with age
previously proved to be a complex matter. In some
cross-sectional studies, a quadratic decline function of
AMH with age best fit the data [12, 14, 15, 18], while
others built models with polynomials or flexible splines
[6, 13, 16, 17]. Consequently, the proposed relationship
of AMH with age took on various forms. Some models
estimated the decline of age-specific AMH levels with
age to be parallel [6, 14, 15], where others reported con-
verging AMH levels with higher age [12, 13, 16–18].
With our longitudinal data, we show that the individual
decline of AMH levels is more approximate to the latter
observation, as the differences between low and high
AMH levels decreased with age. The reality of the
physiology of the decline of ovarian reserve furthermore
appears more complex than could previously be studied,
as the individual decline rates depended on both initial
AMH levels and age or time to menopause.
The notion of differing decline rates of AMH was pre-
viously put forward by Faddy et al. [25], who suggested
that the decline rate of follicles accelerates after reaching
a certain numeric threshold. The number of follicles at
this threshold was primarily estimated to be around
25,000 [26], and later hypothesized to differ per individ-
ual [25]. Thilagam [21] recently extended this mathem-
atical model to include the influence of other hormones
involved in ovarian aging. Indeed, our results indicate
that there are more factors at play. We observed an
average acceleration of AMH decline with chronological
age, while the average decline rate gradually decreased
with time to menopause. This could mean that follicle
quantity changes are more dependent on chronological
rather than reproductive aging, or could be an indication
of increased AMH production per follicle due to
increasing FSH levels nearer to menopause [27]. More-
over, higher initial AMH levels were first associated with
a slower AMH decline rate, but later with a quicker
decline. This could potentially mean that the suggested
inhibitory effect of AMH on follicle recruitment [28–30]
is effective up to a certain age or ovarian reserve thresh-
old. This concept was previously brought up in a mouse
study, in which the decline of growing follicles and AMH
levels accelerated only later in reproductive life [31], lead-
ing to the hypothesis that compensatory mechanisms are
present earlier on. In any case, this observation may prove
detrimental for the hopes of improved reproductive age
estimation with repeated AMH measurements.
Current time to menopause estimations with single
AMH measurements are based on the concept that
comparatively high (or low) AMH levels for age will
remain high (or low) with age. Following this principle, a
lower age-specific AMH level at any age should be associ-
ated with a shorter time to menopause [4, 6, 7, 9–11, 32].
While we did indeed observe differences between women
in different baseline age-specific quartiles, it was surpris-
ing that there was such variability of AMH levels between
women at a given time before menopause. This may in
part explain the currently limited discriminatory capacity
of AMH for time to menopause [32]. A related finding in
this study is the 62.9 % observed AMH levels above the
limit of detection within a year of the FMP. While this
may partly be attributed to the high sensitivity of the
assay, measurement error or recall bias for the timing of
the FMP, earlier research has also suggested that the
follicle pool is not entirely depleted at the time of meno-
pause [2, 26, 33]. It may well be that this critical threshold
differs between women, or that in the minority of the
cases other causes such as hypothalamic dysregulation are
at the root of the cessation of menses [2].
Prior longitudinal studies of AMH decline with age at
menopause are in disagreement on whether AMH
decline rate is associated with time to menopause [5, 8].
Contrary to our current findings, these studies assumed
a linear decline of logAMH with time to menopause. The
rate of decline was assessed over a maximum period of
14 years in 293 women [8], and over six annual intervals
in 50 women [5]. A striking difference with our current
study is the difference in age; Freeman et al. [8] included
women aged between 35 and 48 (mean 41) years and
Sowers et al. [5] included women with a mean age of 42
± 2.7 years (no range provided). This age difference may
explain the perceived linear decline, as we found the
decline rate of AMH to be highest between the ages of
40 and 55, at which time the overall decline trajectory
did appear more or less linear. Importantly, if AMH is
ever to be used for individual estimations of the
remaining number of fertile years in the light of family
planning, the AMH measurements should occur at a far
earlier age than in these studies. Our results indicate
that the currently available prediction models with
AMH decline rate cannot be extrapolated to the ages at
which the measurement of AMH would be most useful.
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The added value of multiple AMH measurements for
the prediction of time to menopause therefore requires
further investigation.
This study is the first to characterize the longitudinal
decline of AMH with regard to age and time to menopause,
in the largest study population to date. Further strengths
include the random selection of study participants, large
age range, standardized data assessment, and storage of the
samples from round 2 at –80 °C. There are no data on the
effects of long-term storage on sample degeneration, but
the selectivity of the picoAMH antibodies to a single bind-
ing site on the N-terminal domain of the AMH molecule
minimizes the risk of measuring degradation products. The
women with no available sample for AMH measurement
smoked more often and had a higher BMI at baseline, sug-
gesting that our results may represent a slightly more
healthy part of the female general population. We were ad-
equately able to correct for smoking status and BMI had no
influence on AMH levels, and therefore do not believe this
to have substantial consequences for the results presented
here. As there were no women below the age of 20 in the
cohort, with the majority of women above the age of 30 at
baseline, our study is limited by the fact that we have
relatively little information of ovarian reserve decline in the
early years of female reproduction.
This longitudinal study reveals that there is no fixed
decline trajectory of AMH. The decline rate of AMH differs
between women and although age-specific AMH levels re-
main distinct, these differences decrease as age progresses.
Moreover, the finding of varying AMH levels between
women at the same time before menopause highlights the
potential limitation of AMH for estimating time to meno-
pause. Future studies of AMH as a predictor of the repro-
ductive lifespan should consider the non-linear decline with
age and time to menopause, the differences in rate of de-
cline, and the converging, rather than parallel, trajectories.
In the light of reproductive aging and family planning, it
would also be interesting to focus on the association of
AMH decline and pregnancies. Levels of AMH were not
associated with time to pregnancy in a prior study [34], and
the wide range of AMH levels in proven fertile women [35]
indicates that there is more to fertility than ovarian reserve.
In a contemporary population-based cohort such as the
Doetinchem Cohort Study, it is difficult to address this
question due to the widespread use of contraceptives and
the burden of collecting reliable information regarding the
menstrual cycle, spontaneous pregnancies, infertility treat-
ment, time to pregnancy, and age at last childbirth. Future
studies, with a younger study population, may be better
suited to answer this question.
Conclusion
In conclusion, this study provides an insight into the
physiology of ovarian reserve decline and paves the way
for studies measuring the true feasibility of the individu-
alized clinical use of single and multiple AMH measure-
ments. Until then, AMH levels with regard to the
reproductive lifespan should be interpreted with caution.
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